FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307450117> ?p ?o ?g. }

• W4307450117 abstract "<h3>Introduction</h3> ADP-A2M4CD8, a next-generation specific peptide enhanced affinity receptor (SPEAR) T-cell therapy supplemented with a CD8α co-receptor, is being evaluated in the Phase 1 SURPASS trial (NCT04044859) in multiple solid tumours, including ovarian cancer. Promising anti-tumour activity, including a 36% overall response rate (1 complete response [CR], 7 partial responses [PR] in 22 evaluable patients; 2 August 2021 data cut-off) and a favourable benefit to risk profile were reported.¹ We report preliminary anti-tumour activity in ovarian cancer and updated safety in all tumours. <h3>Methods</h3> SURPASS is a first-in-human trial evaluating ADP-A2M4CD8 using a modified 3+3 design, with 2 dose cohorts and an expansion cohort.¹ T-cells are collected by leukapheresis, transduced, and infused into the patient after lymphodepletion. Eligible patients express human leukocyte antigen A*02 with melanoma-associated antigen (MAGE)-A4-positive tumours. Patients with ovarian cancer must have received platinum-based chemotherapy and progressed ≤12 months post platinum therapy. <h3>Results</h3> As of 1 August 2022, 14 patients with ovarian cancer had received 1.14–9.95×10⁹ transduced T-cells. Median age was 59 years (range, 40–75); median number of prior systemic therapy regimens was 4 (range, 2–8); median MAGE-A4 expression H-score was 237.5 (range, 95–300). Adverse events in the overall population were consistent with lymphodepletion chemotherapy or cellular therapy; similar safety results were seen in the ovarian cancer subgroup (table 1). There was 1 Grade 5 cytokine release syndrome. Best overall responses were 1 CR, 4 PR, 6 stable disease (SD), 2 progressive disease and 1 not evaluable, giving a 36% overall response rate and a 79% disease control rate (CR+PR+SD, figure 1). <h3>Conclusions</h3> ADP-A2M4CD8 SPEAR T-cell therapy showed preliminary anti-tumour activity in heavily pre-treated patients with MAGE-A4+ advanced ovarian cancer, with tolerable emerging safety results. The trial now includes an anti-programmed death-ligand 1 combination treatment cohort. 1. Hong DS, et al. Ann Oncol. 2021;32(suppl5):540P." @default.
• W4307450117 created "2022-11-01" @default.
• W4307450117 creator A5008158683 @default.
• W4307450117 creator A5019721864 @default.
• W4307450117 creator A5022359317 @default.
• W4307450117 creator A5024433837 @default.
• W4307450117 creator A5025537575 @default.
• W4307450117 creator A5025781878 @default.
• W4307450117 creator A5026095888 @default.
• W4307450117 creator A5033799057 @default.
• W4307450117 creator A5040030971 @default.
• W4307450117 creator A5042255336 @default.
• W4307450117 creator A5048013245 @default.
• W4307450117 creator A5048533977 @default.
• W4307450117 creator A5053069942 @default.
• W4307450117 creator A5055113832 @default.
• W4307450117 creator A5063439924 @default.
• W4307450117 creator A5070881158 @default.
• W4307450117 creator A5079842256 @default.
• W4307450117 creator A5080650099 @default.
• W4307450117 creator A5080668659 @default.
• W4307450117 creator A5084203678 @default.
• W4307450117 date "2022-10-01" @default.
• W4307450117 modified "2023-09-27" @default.
• W4307450117 title "2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer" @default.
• W4307450117 doi "https://doi.org/10.1136/ijgc-2022-esgo.1019" @default.
• W4307450117 hasPublicationYear "2022" @default.
• W4307450117 type Work @default.
• W4307450117 citedByCount "0" @default.
• W4307450117 crossrefType "proceedings-article" @default.
• W4307450117 hasAuthorship W4307450117A5008158683 @default.
• W4307450117 hasAuthorship W4307450117A5019721864 @default.
• W4307450117 hasAuthorship W4307450117A5022359317 @default.
• W4307450117 hasAuthorship W4307450117A5024433837 @default.
• W4307450117 hasAuthorship W4307450117A5025537575 @default.
• W4307450117 hasAuthorship W4307450117A5025781878 @default.
• W4307450117 hasAuthorship W4307450117A5026095888 @default.
• W4307450117 hasAuthorship W4307450117A5033799057 @default.
• W4307450117 hasAuthorship W4307450117A5040030971 @default.
• W4307450117 hasAuthorship W4307450117A5042255336 @default.
• W4307450117 hasAuthorship W4307450117A5048013245 @default.
• W4307450117 hasAuthorship W4307450117A5048533977 @default.
• W4307450117 hasAuthorship W4307450117A5053069942 @default.
• W4307450117 hasAuthorship W4307450117A5055113832 @default.
• W4307450117 hasAuthorship W4307450117A5063439924 @default.
• W4307450117 hasAuthorship W4307450117A5070881158 @default.
• W4307450117 hasAuthorship W4307450117A5079842256 @default.
• W4307450117 hasAuthorship W4307450117A5080650099 @default.
• W4307450117 hasAuthorship W4307450117A5080668659 @default.
• W4307450117 hasAuthorship W4307450117A5084203678 @default.
• W4307450117 hasBestOaLocation W43074501171 @default.
• W4307450117 hasConcept C10205521 @default.
• W4307450117 hasConcept C121608353 @default.
• W4307450117 hasConcept C126322002 @default.
• W4307450117 hasConcept C143998085 @default.
• W4307450117 hasConcept C147483822 @default.
• W4307450117 hasConcept C167672396 @default.
• W4307450117 hasConcept C203014093 @default.
• W4307450117 hasConcept C2776694085 @default.
• W4307450117 hasConcept C2777371436 @default.
• W4307450117 hasConcept C2777701055 @default.
• W4307450117 hasConcept C2780427987 @default.
• W4307450117 hasConcept C28328180 @default.
• W4307450117 hasConcept C2908647359 @default.
• W4307450117 hasConcept C54355233 @default.
• W4307450117 hasConcept C71924100 @default.
• W4307450117 hasConcept C86803240 @default.
• W4307450117 hasConcept C90924648 @default.
• W4307450117 hasConcept C99454951 @default.
• W4307450117 hasConceptScore W4307450117C10205521 @default.
• W4307450117 hasConceptScore W4307450117C121608353 @default.
• W4307450117 hasConceptScore W4307450117C126322002 @default.
• W4307450117 hasConceptScore W4307450117C143998085 @default.
• W4307450117 hasConceptScore W4307450117C147483822 @default.
• W4307450117 hasConceptScore W4307450117C167672396 @default.
• W4307450117 hasConceptScore W4307450117C203014093 @default.
• W4307450117 hasConceptScore W4307450117C2776694085 @default.
• W4307450117 hasConceptScore W4307450117C2777371436 @default.
• W4307450117 hasConceptScore W4307450117C2777701055 @default.
• W4307450117 hasConceptScore W4307450117C2780427987 @default.
• W4307450117 hasConceptScore W4307450117C28328180 @default.
• W4307450117 hasConceptScore W4307450117C2908647359 @default.
• W4307450117 hasConceptScore W4307450117C54355233 @default.
• W4307450117 hasConceptScore W4307450117C71924100 @default.
• W4307450117 hasConceptScore W4307450117C86803240 @default.
• W4307450117 hasConceptScore W4307450117C90924648 @default.
• W4307450117 hasConceptScore W4307450117C99454951 @default.
• W4307450117 hasLocation W43074501171 @default.
• W4307450117 hasOpenAccess W4307450117 @default.
• W4307450117 hasPrimaryLocation W43074501171 @default.
• W4307450117 hasRelatedWork W1967715255 @default.
• W4307450117 hasRelatedWork W1974496092 @default.
• W4307450117 hasRelatedWork W2365914703 @default.
• W4307450117 hasRelatedWork W2410583709 @default.
• W4307450117 hasRelatedWork W2552554696 @default.
• W4307450117 hasRelatedWork W2948610106 @default.
• W4307450117 hasRelatedWork W3047309708 @default.
• W4307450117 hasRelatedWork W4250083105 @default.
• W4307450117 hasRelatedWork W4310753606 @default.
• W4307450117 hasRelatedWork W4362706485 @default.

• next